Harnessing the Innate Mechanism of Gene Activation

MiNA Therapeutics is a clinical-stage biotechnology company harnessing an innate mechanism of gene activation to enable the development of new medicines that restore normal function to the patients' cells.

The Company is focused on developing RNAa, a new mode of RNA therapies that can activate protein production in targeted cells, making MiNA the first company to use RNA to activate genes in order to target undruggable proteins.

MiNA has developed a first-in-class therapy that reduces immune suppression in the tumor microenvironment, and has demonstrated positive initial results for patients with advanced liver cancer.


Investing partner / fund: